Telix Pharmaceuticals announces Health Canada approval of Illuccix

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Oct 04 2024

0mins

Health Canada Approval: Telix Pharmaceuticals has received approval from Health Canada for Illuccix to be used in selecting patients with progressive metastatic castration-resistant prostate cancer for PSMA-targeted radionuclide therapy.
Expanded Clinical Utility: This approval expands the use of Illuccix, which was previously approved for staging and re-staging prostate cancer, and it is now available through a distribution network servicing 265 hospitals and clinics across Canada.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.